Table 1.

Overview on a selection of recently developed scores in CLL

	Wierda et al, 200716	Wierda et al, 201119	Haferlach et al, 201020	Rossi et al, 201321	Pflug et al, 201417	CLL-IPI working group, 2016
Number of patients	1674	930	399	637	1948	3472
Application	All stages, previously untreated	Early stage only	Early stage only	All stages, previously untreated	All stages, previously untreated	All stages, previously untreated
Clinical implications	OS and TTT	TTT	oS and TTT	OS	OS	OS
Factors included	Age, β2-M, ALC, Hb, gender, Rai stage, involved LNA	unmutated IGHV, diameter palpable LN, del(11q) or del(17p), involved LNA, LDH	Age, WBC, del(17p), unmutated IGHV, IGHV locus translocation, N cytogenetic aberrations	TP53 del/mut, BIRC3 del/mut, NOTCH1 mut, SF3B1 mut, del(11q), trisomy 12 normal genetics, del(13q)	age, gender, ECOG, thymidine kinase, β2-M, unmutated IGHV, del(17p), del(11q)	TP53 del/mut, unmutated IGHV, β2-M, clinical stage, age
Validation	Concordance index	Internal	None	Internal	Internal and external	Internal and external
Definition of risk groups	Low Intermediate High	Prognostic nomogram	Favorable Intermediate Unfavorable	Very low Low Intermediate High	Low Intermediate High Very high	Low Intermediate High Very high

ALC, absolute lymphocyte count; β₂-M, beta₂-microglobulin; Hb, hemoglobin; LN, lymph node; LNA, lymph node areas; WBC, white blood cell count.